Treatment-Resistant Depression With a Subtle Bipolar Signal
A 41-year-old woman with major depressive disorder has failed adequate trials of sertraline 200 mg daily (10 weeks) and bupropion XL 300 mg daily (8 weeks), with partial response only. Current PHQ-9 is 17. She describes 4 years of recurrent depressions, each lasting 4-6 months, with complete inter-episode recovery. On careful questioning, she recalls two periods in her early 30s when she 'barely needed sleep for a week, got tons done, and spent $3,000 on things I didn't need,' but she did not seek care and does not consider herself 'bipolar.' She has no current suicidal ideation, no psychotic features, and no substance use. Family history includes a mother with 'severe depression' treated with lithium.
1. How does the history of brief sleep-independent activation and overspending change your diagnostic assessment, and what is the key uncertainty?
Read the worked answer
This history raises the possibility of bipolar II disorder and should prompt a formal reassessment before escalating antidepressant monotherapy.
Reasoning:
- The reported periods - decreased need for sleep (not insomnia), increased goal-directed activity, and impulsive overspending for about a week - meet the symptom pattern of hypomania. Hypomania requires ≥4 consecutive days of abnormally elevated/expansive or irritable mood plus increased energy/goal-directed activity with ≥3 (if elevated) qualifying symptoms, and observable change not due to substances or another condition.
- The mother's lithium-treated 'severe depression' is a soft but meaningful clue toward a bipolar diathesis.
Key uncertainties:
- Duration and impairment are not yet established. Was the activation truly ≥4 days, and was it observable by others? Retrospective recall is unreliable, so collateral is essential.
- No clear distinct episode boundary is documented; it could represent antidepressant activation, a mixed feature, or normal productivity.
The exam-tested move: do not reflexively label treatment-resistant unipolar depression and add a third antidepressant or augment with another activating agent until the bipolar question is clarified. Obtain collateral, reconstruct a mood timeline, and screen with a structured tool (e.g., MDQ/CIDI-based interview).
2. Assuming the hypomanic history is confirmed, outline a treatment plan and explain why the prior regimen is problematic.
Read the worked answer
Plan (confirmed bipolar II with current depression):
- Rationale for change: Antidepressant monotherapy in bipolar depression risks treatment-emergent hypomania/mania, mixed states, and cycle acceleration. The current regimen (sertraline + bupropion, both activating) is a poor fit if a bipolar diathesis is confirmed.
- Mood stabilizer as the backbone: Start a guideline-supported mood stabilizer (e.g., quetiapine or lurasidone for bipolar depression, or lithium/lamotrigine depending on polarity and tolerability). Titrate slowly and monitor (lithium levels/renal/thyroid; lamotrigine rash titration).
- Antidepressant management: Generally taper or discontinue the antidepressant once a mood stabilizer is established; if an antidepressant is retained, it should be paired with a mood stabilizer and monitored for switch.
- Psychoeducation: Explain the diagnosis, the sleep–mood link, and early-warning signs; emphasize sleep regularity and avoidance of stimulants.
- Monitoring: Track mood with a chart, screen for suicidality at each visit, and reassess response in 4-6 weeks.
Exam-tested judgment: The diagnosis drives the pharmacologic strategy - confirming bipolarity before intensifying antidepressant treatment is the pivotal decision, and the plan must pair any antidepressant with a mood stabilizer rather than escalate monotherapy.